SBIO ETF Rallies on Clinical Trial Wins & M&A Demand

The biotechnology sector continues to ride a massive wave of medical innovation, and ETFs like the ALPS Medical Breakthroughs ETF (SBIO B-) appear to be capturing the upside. SBIO posted a solid 5% gain in August, fueled by positive clinical trial data and an accelerating pace of industry mergers and acquisitions.Key Takeaways SBIO gained 5% in August and has returned 24.57% year to date and 75.38% over the past year. SBIO’s focus on small- and mid-cap companies with Phase II and Phase III programs gives investors exposure to potentially market-moving clinical, regulatory and commercial catalysts. Big Pharma’s need to replenish pipelines ahead of patent expirations is creating acquisition opportunities, with six SBIO portfolio companies receiving takeout bids over the past 12 months. Capitalizing on Late-Stage InnovationSBIO posted a 24.57% year-to-date return through August. Even more impressive is its long-term momentum. Over the last year, SBIO has delivered a whopping 75.38% return for its investors, outpacing broader market benchmarks. SBIO’s underlying strategy focuses on mid- and small-cap biotechnology and pharmaceutical companies valued between $200 million and $5 billion that have at least one drug in Phase II or Phase III FDA clinical trials. This targeted, late-stage approach gives the fund exposure to companies approaching pivotal clinical milestones and potential medical breakthroughs. See More: Advisors Rethink Equal Weighting Amid Equity ConcentrationM&A Adds Another CatalystThe appeal of late-stage biotech extends beyond potential drug approvals. Big Pharma is increasingly willing to pay substantial premiums for promising clinical-stage assets. Companies confronting looming patent expirations and the need to replenish their pipelines are particularly driven to do so. Since the start of 2026, several SBIO holdings have attracted major acquisition interest. In total, six SBIO portfolio companies have received takeout bids over the past 12 months, including Day One Biopharmaceuticals, Apellis Pharmaceuticals and Apogee Therapeutics.Key Holdings Fuel SBIO’s Momentum SBIO’s August gains were driven by a range of company-specific developments. For example, Kura Oncology Inc. (0.58% weight*) gained 40.4% after reporting $9.1 million in net product revenue for Komzifti, its oral treatment for acute myeloid leukemia, in its second full quarter on the market. Revenue rose 57% from the first quarter, supported by approximately 115 new patient starts. The results gave investors early evidence that the drug is gaining traction commercially. Zai Lab Ltd. (1.42% weight*) rose 39.35% after the FDA granted Orphan Drug Designation to Zocilurtatug pelitecan (Zoci), an antibody-drug conjugate being developed for neuroendocrine carcinomas. Zai Lab also reported sequential revenue growth and continued profitability, while planning three registrational studies for Zoci by year-end. Amylyx Pharmaceuticals Inc. (1.93% weight) jumped 66.17% after its Phase III LUCIDITY trial of Avexitide met its primary and all secondary endpoints in patients with post-bariatric hypoglycemia. The treatment reduced clinically significant hypoglycemic events by 55% compared with a placebo. Amylyx plans to seek regulatory approval by year-end, with a potential launch in 2027. Arcturus Therapeutics Holdings Inc. (0.22% weight) surged more than 156% after regaining global rights to its self-amplifying mRNA vaccine portfolio, including the approved COVID-19 vaccine Kostaive. The agreement provided $12 million in cash and released approximately $16 million in liabilities, extending the company’s cash runway. Arcturus also completed enrollment and dosing in a Phase II study of ARCT-810 for a rare inherited metabolic disorder.From Drug Sales to FDA Milestones Together, these companies highlight the range of catalysts that can drive SBIO’s small- and midcap holdings higher. With biotech M&A activity remaining robust and therapeutic innovation continuing to advance, SBIO offers investors targeted exposure to the companies developing the next generation of healthcare treatments. For more news, information, and analysis, visit the ETF Building Blocks Content Hub. VettaFi LLC (“VettaFi”) is the index provider for SBIO, for which it receives an index licensing fee. However, SBIO is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of SBIO.